Establishment of the novel targeted therapy and its biomarker for the patients with renal cell cancer

我们分析了舒尼替尼在常规临床实践中对转移性肾细胞癌（RCC）患者的治疗疗效和安全性。此外，我们调查了这些患者的预后临床病理因素。舒尼替尼在临床实践中对日本转移性RCC患者具有良好的疗效/安全性特征。在分子靶向治疗的时代，MSKCC预后因子似乎仍然是预测转移性RCC患者生存的有效指标。此外，我们在体外和体内研究了舒尼替尼对RCC进展的抑制作用。在临床或实验可达到的血清水平（100 nM）下，舒尼替尼不会抑制体外RCC细胞的生长。1μM）。然而，舒尼替尼阻止<Luc>了骨转移小鼠模型中ACHN^ RCC细胞的生长。舒尼替尼组小鼠破骨细胞数量明显少于对照组。在舒尼替尼治疗的前4周内，转移性RCC患者的血清和尿液NTx水平显著下降。

We analyzed the treatment efficacy and safety profile of sunitinib for patients with metastatic renal cell cancer(RCC) in ordinary clinical practice. In addition, we investigated the prognostic clinicopathological factors in these patients. Sunitinib has a favorable efficacy/safety profile for Japanese metastatic RCC patients in clinical practice. MSKCC prognostic factors seem to be still valid to predict survival in metastatic RCC in the era of molecular targeted therapy.In addition, we investigated the inhibitory effect of sunitinib against the progression of RCC in vitro and in vivo. Sunitinib did not inhibit the growth of RCC cells in vitro at clinically or experimentally achievable serum levels(100 nM. 1μM). However, sunitinib prevented the growth of ACHN^<Luc> RCC cells in the bone metastatic mouse model. The number of osteoclasts in sunitinib-treated mice was significantly less than that in control mice. Serum and urine levels of NTx in patients with metastatic RCC declined significantly during the first 4 weeks of sunitinib treatment.